NRx Pharmaceuticals Enhances Communications Strategy with IBN for Breakthrough Therapies

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has partnered with IBN to enhance its corporate communications strategy, focusing on its innovative treatments for suicidal depression and PTSD. The company is making significant strides with its FDA-designated therapies, NRX-100 and NRX-101, including an NDA for NRX-100 and plans for additional regulatory filings. Additionally, NRx has launched HOPE Therapeutics, a subsidiary aimed at creating a national psychiatric care network, with intentions for a public spin-out. IBN's role will be to amplify investor awareness and outreach through its extensive media portfolio. For more details, visit the full press release.

NRx Pharmaceuticals is at the forefront of developing therapeutics for central nervous system disorders, with NRX-101 being an FDA-designated Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. The company is also advancing NRX-100 (IV ketamine) for suicidal depression, leveraging data from clinical trials and French health authorities. NRx's efforts are supported by Fast Track Designation from the US FDA, highlighting the potential impact of its treatments. Investors and interested parties can stay updated through the company's newsroom at https://ibn.fm/NRXP.